ANI Pharmaceuticals, Inc. (ANIP) 10-Year Financial Performance & Capital Metrics

ANIP • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsComplex Generics

AboutANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.Show more

Revenue $614M +26.2%
EBITDA $68M -36.0%
Net Income -$19M -198.6%
EPS (Diluted) -1.04 -210.6%
Gross Margin 59.27% -5.5%
EBITDA Margin 11.12% -49.3%
Operating Margin 0.1% -99.0%
Net Margin -3.01% -178.2%
ROE -4.18% -188.6%
ROIC 0.06% -99.0%
Debt/Equity 1.46 +133.3%
Interest Coverage 0.03 -98.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 24.4%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y27.07%

5Y24.36%

3Y41.66%

TTM48.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM637.13%

EPS CAGR

10Y-

5Y-

3Y-

TTM401.29%

ROCE

10Y Avg3.4%

5Y Avg-2.03%

3Y Avg0.48%

Latest0.06%

Peer Comparison

Complex Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AMPHAmphastar Pharmaceuticals, Inc.	1.19B	26.00	8.50	13.59%	15.43%	14.37%	14.43%	0.89
AMRXAmneal Pharmaceuticals, Inc.	4.15B	13.19	-34.71	16.73%	0.2%	-13.94%	5.31%
ANIPANI Pharmaceuticals, Inc.	1.92B	85.29	-82.01	26.2%	4.61%	7.53%	2.46%	1.46

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	76.32M	128.62M	176.84M	201.58M	206.55M	208.47M	216.14M	316.38M	486.82M	614.38M
Revenue Growth %	0.36%	0.69%	0.37%	0.14%	0.02%	0.01%	0.04%	0.46%	0.54%	0.26%
Cost of Goods Sold+	12.69M	48.78M	79.03M	73.02M	63.15M	87.16M	100.61M	138.78M	181.51M	250.21M
COGS % of Revenue	0.17%	0.38%	0.45%	0.36%	0.31%	0.42%	0.47%	0.44%	0.37%	0.41%
Gross Profit+	63.63M	79.84M	97.81M	128.55M	143.39M	121.32M	115.53M	177.6M	305.3M	364.17M
Gross Margin %	0.83%	0.62%	0.55%	0.64%	0.69%	0.58%	0.53%	0.56%	0.63%	0.59%
Gross Profit Growth %	0.43%	0.25%	0.23%	0.31%	0.12%	-0.15%	-0.05%	0.54%	0.72%	0.19%
Operating Expenses+	30.93M	53.08M	68.58M	93.19M	127.04M	137.33M	155.32M	212.88M	258.33M	363.58M
OpEx % of Revenue	0.41%	0.41%	0.39%	0.46%	0.62%	0.66%	0.72%	0.67%	0.53%	0.59%
Selling, General & Admin	21.16M	27.83M	31.58M	44.06M	55.84M	64.99M	84.29M	124.04M	161.7M	249.64M
SG&A % of Revenue	0.28%	0.22%	0.18%	0.22%	0.27%	0.31%	0.39%	0.39%	0.33%	0.41%
Research & Development	2.87M	2.91M	9.07M	15.39M	19.81M	16M	11.37M	22.32M	34.29M	44.58M
R&D % of Revenue	0.04%	0.02%	0.05%	0.08%	0.1%	0.08%	0.05%	0.07%	0.07%	0.07%
Other Operating Expenses	41K	-74K	55K	-550K	51.39M	56.35M	59.66M	66.52M	62.35M	69.36M
Operating Income+	32.7M	20.08M	28.33M	35.36M	16.35M	-16.02M	-39.79M	-35.28M	46.97M	584K
Operating Margin %	0.43%	0.16%	0.16%	0.18%	0.08%	-0.08%	-0.18%	-0.11%	0.1%	0%
Operating Income Growth %	0.63%	-0.39%	0.41%	0.25%	-0.54%	-1.98%	-1.48%	0.11%	2.33%	-0.99%
EBITDA+	39.6M	42.42M	56.26M	69.1M	60.96M	28.62M	7.46M	24.37M	106.76M	68.31M
EBITDA Margin %	0.52%	0.33%	0.32%	0.34%	0.3%	0.14%	0.03%	0.08%	0.22%	0.11%
EBITDA Growth %	0.66%	0.07%	0.33%	0.23%	-0.12%	-0.53%	-0.74%	2.27%	3.38%	-0.36%
D&A (Non-Cash Add-back)	6.9M	22.34M	27.93M	33.74M	44.61M	44.64M	47.25M	59.65M	59.79M	67.73M
EBIT	32.7M	33.96M	29.23M	34.81M	16.12M	-16.51M	-44.14M	-34.61M	46.81M	-4.61M
Net Interest Income+	-11.01M	-11.33M	-12.04M	-14.76M	-12.97M	-9.45M	-11.92M	-28.05M	-26.94M	-17.6M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	11.01M	11.33M	12.04M	14.76M	12.97M	9.45M	11.92M	28.05M	26.94M	17.6M
Other Income/Expense	-10.97M	-11.4M	-11.98M	-15.31M	-13.19M	-9.95M	-16.27M	-27.38M	-27.1M	-22.8M
Pretax Income+	21.73M	8.68M	16.35M	20.05M	3.16M	-25.96M	-56.06M	-62.66M	19.87M	-22.21M
Pretax Margin %	0.28%	0.07%	0.09%	0.1%	0.02%	-0.12%	-0.26%	-0.2%	0.04%	-0.04%
Income Tax+	6.36M	4.74M	17.43M	4.56M	-2.94M	-3.41M	-13.46M	-14.77M	1.09M	-3.69M
Effective Tax Rate %	0.71%	0.45%	-0.07%	0.77%	1.93%	0.87%	0.76%	0.76%	0.94%	0.83%
Net Income+	15.38M	3.93M	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M
Net Margin %	0.2%	0.03%	-0.01%	0.08%	0.03%	-0.11%	-0.2%	-0.15%	0.04%	-0.03%
Net Income Growth %	-0.47%	-0.74%	-1.27%	15.4%	-0.61%	-4.7%	-0.89%	-0.12%	1.39%	-1.99%
Net Income (Continuing)	15.38M	3.93M	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.32	0.34	-0.09	1.32	0.50	-1.88	-3.40	-3.05	0.94	-1.04
EPS Growth %	-0.49%	-0.74%	-1.27%	15.16%	-0.62%	-4.76%	-0.81%	0.1%	1.31%	-2.11%
EPS (Basic)	1.34	0.34	-0.09	1.33	0.51	-1.88	-3.40	-3.05	0.95	-1.04
Diluted Shares Outstanding	11.56M	11.57M	11.55M	11.77M	12.04M	11.96M	12.6M	16.26M	18.19M	19.32M
Basic Shares Outstanding	11.37M	11.45M	11.55M	11.68M	11.84M	11.96M	12.6M	16.26M	18M	19.32M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	192.58M	103.01M	131.6M	152.88M	187.69M	170.32M	321.77M	344.26M	519.82M	527.68M
Cash & Short-Term Investments	154.68M	27.36M	31.14M	43.01M	62.33M	7.86M	100.3M	48.23M	221.12M	151.17M
Cash Only	154.68M	27.36M	31.14M	43.01M	62.33M	7.86M	100.3M	48.23M	221.12M	144.86M
Short-Term Investments	0	0	0	0	0	0	0	0	0	6.31M
Accounts Receivable	21.93M	45.9M	58.79M	64.84M	72.13M	95.79M	128.53M	165.44M	162.08M	221.73M
Days Sales Outstanding	104.89	130.24	121.34	117.41	127.46	167.72	217.05	190.86	121.52	131.73
Inventory	13.39M	26.18M	37.73M	40.5M	48.16M	60.8M	81.69M	105.36M	111.2M	136.78M
Days Inventory Outstanding	384.99	195.92	174.24	202.45	278.36	254.63	296.37	277.08	223.6	199.53
Other Current Assets	1.45M	3.56M	2.78M	4.52M	4M	0	3.67M	21.41M	25.42M	18.01M
Total Non-Current Assets+	92.68M	219.86M	280.53M	277.73M	269.09M	290.87M	449.82M	415.83M	384.61M	756.01M
Property, Plant & Equipment	7.13M	11M	20.4M	38.09M	40.55M	41.27M	52.67M	43.25M	44.59M	56.86M
Fixed Asset Turnover	10.70x	11.70x	8.67x	5.29x	5.09x	5.05x	4.10x	7.32x	10.92x	10.80x
Goodwill	1.84M	1.84M	1.84M	3.58M	3.58M	3.58M	27.89M	28.22M	28.22M	59.99M
Intangible Assets	66.4M	175.79M	229.79M	201.6M	180.39M	188.51M	294.12M	251.63M	209.01M	541.83M
Long-Term Investments	-17.32M	5M	800K	5.02M	0	5M	5M	0	6.2M	0
Other Non-Current Assets	17.32M	0	5.04M	1.47M	6.25M	802K	2.21M	11.36M	5.87M	12.22M
Total Assets+	285.26M	322.86M	412.14M	430.6M	456.79M	461.19M	771.6M	760.09M	904.42M	1.28B
Asset Turnover	0.27x	0.40x	0.43x	0.47x	0.45x	0.45x	0.28x	0.42x	0.54x	0.48x
Asset Growth %	0.08%	0.13%	0.28%	0.04%	0.06%	0.01%	0.67%	-0.01%	0.19%	0.42%
Total Current Liabilities+	11.76M	31.95M	39.23M	165.55M	61.68M	78.56M	87.54M	99.44M	145.48M	193.68M
Accounts Payable	2.07M	3.39M	3.63M	8.88M	14.61M	11.26M	22.97M	29.3M	36.68M	45.66M
Days Payables Outstanding	59.41	25.36	16.76	44.41	84.42	47.16	83.32	77.07	73.76	66.6
Short-Term Debt	0	0	3.35M	115.72M	9.94M	13.24M	850K	850K	850K	9.17M
Deferred Revenue (Current)	0	0	1000K	711K	451K	80K	87K	0	0	0
Other Current Liabilities	8.5M	8.15M	29.94M	31.69M	20.33M	33.39M	44.27M	43.71M	65.73M	77.03M
Current Ratio	16.38x	3.22x	3.35x	0.92x	3.04x	2.17x	3.68x	3.46x	3.57x	2.72x
Quick Ratio	15.24x	2.40x	2.39x	0.68x	2.26x	1.39x	2.74x	2.40x	2.81x	2.02x
Cash Conversion Cycle	430.46	300.8	278.81	275.45	321.41	375.19	430.1	390.87	271.36	264.66
Total Non-Current Liabilities+	113.43M	121.27M	198.15M	67.79M	182.32M	186.93M	325.32M	322.11M	301.35M	661.49M
Long-Term Debt	113.43M	120.64M	198.15M	67.3M	175.81M	172.44M	286.52M	285.67M	284.82M	614.92M
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	7.59M	9.49M	0	0	0
Other Non-Current Liabilities	0	625K	0	496K	6.51M	14.48M	38.8M	36.44M	16.53M	46.57M
Total Liabilities	125.18M	153.22M	237.38M	233.34M	244M	265.49M	412.86M	421.55M	446.82M	855.17M
Total Debt+	113.43M	120.64M	201.51M	183.01M	185.75M	185.69M	287.37M	286.52M	285.67M	624.09M
Net Debt	-41.26M	93.28M	170.36M	140.01M	123.42M	177.82M	187.07M	238.29M	64.55M	479.23M
Debt / Equity	0.71x	0.71x	1.15x	0.93x	0.87x	0.95x	0.80x	0.85x	0.62x	1.46x
Debt / EBITDA	2.86x	2.84x	3.58x	2.65x	3.05x	6.49x	38.53x	11.76x	2.68x	9.14x
Net Debt / EBITDA	-1.04x	2.20x	3.03x	2.03x	2.02x	6.21x	25.08x	9.78x	0.60x	7.02x
Interest Coverage	2.97x	1.77x	2.35x	2.40x	1.26x	-1.69x	-3.34x	-1.26x	1.74x	0.03x
Total Equity+	160.08M	169.65M	174.76M	197.26M	212.79M	195.7M	358.74M	338.54M	457.6M	428.53M
Equity Growth %	0.15%	0.06%	0.03%	0.13%	0.08%	-0.08%	0.83%	-0.06%	0.35%	-0.06%
Book Value per Share	13.85	14.66	15.13	16.76	17.67	16.36	28.48	20.82	25.15	22.18
Total Shareholders' Equity	160.08M	169.65M	174.76M	197.26M	212.79M	195.7M	358.74M	338.54M	457.6M	428.53M
Common Stock	1K	1K	1K	1K	1K	1K	1K	1K	2K	2K
Retained Earnings	-4.35M	-2.92M	-4.01M	11.49M	17.58M	-4.97M	-47.77M	-97.29M	-80.13M	-100.28M
Treasury Stock	0	0	-259K	-659K	-723K	-2.25M	-3.13M	-5.09M	-10.08M	-21.04M
Accumulated OCI	-4.45M	-5.39M	-6.59M	-379K	-4.87M	-11.44M	-3.06M	12.17M	8.86M	5.34M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	17.26M	27.47M	39.42M	67.07M	45.63M	15.27M	3.32M	-31.2M	118.96M	64.02M
Operating CF Margin %	0.23%	0.21%	0.22%	0.33%	0.22%	0.07%	0.02%	-0.1%	0.24%	0.1%
Operating CF Growth %	-0.22%	0.59%	0.43%	0.7%	-0.32%	-0.67%	-0.78%	-10.39%	4.81%	-0.46%
Net Income	15.38M	3.93M	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M
Depreciation & Amortization	6.9M	22.34M	27.93M	33.74M	44.61M	44.64M	47.25M	59.65M	59.79M	67.73M
Stock-Based Compensation	3.86M	6.07M	6.09M	6.78M	9.22M	12.94M	10.49M	14.6M	20.65M	29.34M
Deferred Taxes	-1.88M	-8.91M	3.56M	-5.18M	-9.13M	-13.21M	-16.75M	-15.25M	-11.74M	-21.91M
Other Non-Cash Items	6.87M	13.97M	8.57M	10.27M	9.42M	6.07M	5.02M	8.99M	6.62M	18.56M
Working Capital Changes	-13.86M	-9.93M	-5.65M	5.97M	-14.58M	-12.63M	-84K	-51.3M	24.86M	-11.19M
Change in Receivables	-4.63M	-23.96M	-12.89M	-4.74M	-7.29M	-23.66M	-5.55M	-36.91M	3.36M	-21.09M
Change in Inventory	-5.87M	-1.94M	5.36M	-379K	-7.66M	-2.76M	3.22M	-23.63M	-5.84M	-21.29M
Change in Payables	-1.03M	1.08M	3K	3.47M	5.04M	-2.29M	10.17M	5.04M	7.55M	479K
Cash from Investing+	-32.68M	-154.06M	-107.99M	-27.38M	-27.55M	-68.32M	-105.48M	-15.74M	-18.51M	-404.72M
Capital Expenditures	-32.68M	-149.06M	-107.99M	-10.91M	-27.55M	-6.13M	-2.56M	-8.88M	-8.87M	-16.24M
CapEx % of Revenue	0.43%	1.16%	0.61%	0.05%	0.13%	0.03%	0.01%	0.03%	0.02%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-30.5M	-5M	-97.62M	-5.17M	0	-62.19M	-18.43M	-6.83M	-9.64M	12.8M
Cash from Financing+	1.07M	-729K	72.36M	-27.82M	1.25M	-1.44M	194.59M	-5.13M	67.44M	264.94M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-190K	-1.63M	-1.63M	-1.63M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.18M	323K	-2.38M	-24.34M	-118.75M	618K	2.07M	1.46M	-3.5M	-67.69M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-15.42M	-121.59M	-68.57M	56.16M	18.08M	-53.05M	-20.32M	-47.66M	100.45M	47.06M
FCF Margin %	-0.2%	-0.95%	-0.39%	0.28%	0.09%	-0.25%	-0.09%	-0.15%	0.21%	0.08%
FCF Growth %	-0.12%	-6.89%	0.44%	1.82%	-0.68%	-3.93%	0.62%	-1.35%	3.11%	-0.53%
FCF per Share	-1.33	-10.51	-5.94	4.77	1.50	-4.43	-1.61	-2.93	5.52	2.44
FCF Conversion (FCF/Net Income)	1.12x	6.98x	-36.63x	4.33x	7.49x	-0.68x	-0.08x	0.65x	6.33x	-3.46x
Interest Paid	4.15M	4.08M	3.76M	6.29M	6.09M	6.93M	9.71M	21.48M	31.43M	24.38M
Taxes Paid	13.26M	9.54M	17.79M	6.4M	10.03M	4.98M	10.37M	288K	1.23M	19.06M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.25%	2.39%	-0.62%	8.33%	2.97%	-11.04%	-15.37%	-13.74%	4.72%	-4.18%
Return on Invested Capital (ROIC)	24.49%	7.89%	6.99%	7.77%	3.64%	-3.38%	-6.49%	-4.71%	6.41%	0.06%
Gross Margin	83.37%	62.07%	55.31%	63.77%	69.42%	58.19%	53.45%	56.13%	62.71%	59.27%
Net Margin	20.14%	3.06%	-0.61%	7.69%	2.95%	-10.82%	-19.71%	-15.14%	3.86%	-3.01%
Debt / Equity	0.71x	0.71x	1.15x	0.93x	0.87x	0.95x	0.80x	0.85x	0.62x	1.46x
Interest Coverage	2.97x	1.77x	2.35x	2.40x	1.26x	-1.69x	-3.34x	-1.26x	1.74x	0.03x
FCF Conversion	1.12x	6.98x	-36.63x	4.33x	7.49x	-0.68x	-0.08x	0.65x	6.33x	-3.46x
Revenue Growth	36.36%	68.53%	37.49%	13.99%	2.47%	0.93%	3.67%	46.38%	53.87%	26.2%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Sales of Generics and Other	-	-	-	-	-	-	-	-	-	320.03M
Total Sales of Generics and Other Growth	-	-	-	-	-	-	-	-	-	-
Sales of rare disease pharmaceutical products	-	-	-	-	-	-	-	-	112.12M	229.6M
Sales of rare disease pharmaceutical products Growth	-	-	-	-	-	-	-	-	-	104.79%
Sales of Established Brands	-	-	-	-	-	-	-	-	-	64.74M
Sales of Established Brands Growth	-	-	-	-	-	-	-	-	-	-
Rare Disease	-	-	-	-	-	-	-	41.69M	269.45M	-
Rare Disease Growth	-	-	-	-	-	-	-	-	546.36%	-
Generics, Established Brands, and Other	-	-	-	-	-	-	-	274.7M	105.25M	-
Generics, Established Brands, and Other Growth	-	-	-	-	-	-	-	-	-61.69%	-
Sales of generic pharmaceutical products	-	-	-	-	-	-	143.57M	-	-	-
Sales of generic pharmaceutical products Growth	-	-	-	-	-	-	-	-	-	-
Sales of branded pharmaceutical products	-	-	-	-	-	-	47.56M	-	-	-
Sales of branded pharmaceutical products Growth	-	-	-	-	-	-	-	-	-	-
Royalties from licensing agreements	-	-	-	-	-	-	11.79M	-	-	-
Royalties from licensing agreements Growth	-	-	-	-	-	-	-	-	-	-
Sales of contract manufactured products	-	-	-	-	-	-	3.8M	-	-	-
Sales of contract manufactured products Growth	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	1.86M	-	-	-
Other Growth	-	-	-	-	-	-	-	-	-	-
Product development services	-	-	-	-	-	-	1.31M	-	-	-
Product development services Growth	-	-	-	-	-	-	-	-	-	-
Sales Of Generic Pharmaceutical Products	-	-	-	117.45M	-	147.26M	-	-	-	-
Sales Of Generic Pharmaceutical Products Growth	-	-	-	-	-	-	-	-	-	-
Sales Of Branded Pharmaceutical Products	-	-	-	60.55M	-	47.96M	-	-	-	-
Sales Of Branded Pharmaceutical Products Growth	-	-	-	-	-	-	-	-	-	-
Sales Of Contract Manufactured Products	-	-	-	6.3M	8.1M	6.8M	-	-	-	-
Sales Of Contract Manufactured Products Growth	-	-	-	-	28.57%	-16.05%	-	-	-	-
Product Development Services	-	-	-	1.02M	-	1.86M	-	-	-	-
Product Development Services Growth	-	-	-	-	-	-	-	-	-	-
Royalties From Licensing Agreements	-	-	-	12.5M	-	1.4M	-	-	-	-
Royalties From Licensing Agreements Growth	-	-	-	-	-	-	-	-	-	-
Other Revenues	-	-	-	929K	-	783K	-	-	-	-
Other Revenues Growth	-	-	-	-	-	-	-	-	-	-
Performance Obligation From Prior Period	-	-	-	-	10.2M	-	-	-	-	-
Performance Obligation From Prior Period Growth	-	-	-	-	-	-	-	-	-	-
Products Development Services	-	-	-	-	1.3M	-	-	-	-	-
Products Development Services Growth	-	-	-	-	-	-	-	-	-	-
Unapproved Products	300K	34.3M	27.6M	-	-	-	-	-	-	-
Unapproved Products Growth	-	11333.33%	-19.53%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	604.99M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
Non-US	-	-	-	-	-	-	-	-	-	9.39M
Non-US Growth	-	-	-	-	-	-	-	-	-	-
United States	-	-	-	196.89M	199.66M	-	211.89M	312.43M	486.25M	-
United States Growth	-	-	-	-	1.41%	-	-	47.45%	55.64%	-
Canada	-	-	-	4.69M	6.88M	-	4.24M	3.96M	565K	-
Canada Growth	-	-	-	-	46.78%	-	-	-6.72%	-85.73%	-
U	-	-	-	-	-	202.88M	-	-	-	-
U Growth	-	-	-	-	-	-	-	-	-	-
C	-	-	-	-	-	5.59M	-	-	-	-
C Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ANI Pharmaceuticals, Inc. (ANIP) reported $826.9M in revenue for fiscal year 2024. This represents a 189917% increase from $0.4M in 2011.

ANI Pharmaceuticals, Inc. (ANIP) grew revenue by 26.2% over the past year. This is strong growth.

Yes, ANI Pharmaceuticals, Inc. (ANIP) is profitable, generating $38.1M in net income for fiscal year 2024 (-3.0% net margin).

Dividend & Returns

ANI Pharmaceuticals, Inc. (ANIP) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.

ANI Pharmaceuticals, Inc. (ANIP) has a return on equity (ROE) of -4.2%. Negative ROE indicates the company is unprofitable.

ANI Pharmaceuticals, Inc. (ANIP) generated $135.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

ANI Pharmaceuticals, Inc. (ANIP) 10-Year Financial Performance & Capital Metrics

ANIP • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsComplex Generics

Revenue $614M +26.2%
EBITDA $68M -36.0%
Net Income -$19M -198.6%
EPS (Diluted) -1.04 -210.6%
Gross Margin 59.27% -5.5%
EBITDA Margin 11.12% -49.3%
Operating Margin 0.1% -99.0%
Net Margin -3.01% -178.2%
ROE -4.18% -188.6%
ROIC 0.06% -99.0%
Debt/Equity 1.46 +133.3%
Interest Coverage 0.03 -98.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 24.4%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y27.07%

5Y24.36%

3Y41.66%

TTM48.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM637.13%

EPS CAGR

10Y-

5Y-

3Y-

TTM401.29%

ROCE

10Y Avg3.4%

5Y Avg-2.03%

3Y Avg0.48%

Latest0.06%

Peer Comparison

Complex Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AMPHAmphastar Pharmaceuticals, Inc.	1.19B	26.00	8.50	13.59%	15.43%	14.37%	14.43%	0.89
AMRXAmneal Pharmaceuticals, Inc.	4.15B	13.19	-34.71	16.73%	0.2%	-13.94%	5.31%
ANIPANI Pharmaceuticals, Inc.	1.92B	85.29	-82.01	26.2%	4.61%	7.53%	2.46%	1.46

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	76.32M	128.62M	176.84M	201.58M	206.55M	208.47M	216.14M	316.38M	486.82M	614.38M
Revenue Growth %	0.36%	0.69%	0.37%	0.14%	0.02%	0.01%	0.04%	0.46%	0.54%	0.26%
Cost of Goods Sold+	12.69M	48.78M	79.03M	73.02M	63.15M	87.16M	100.61M	138.78M	181.51M	250.21M
COGS % of Revenue	0.17%	0.38%	0.45%	0.36%	0.31%	0.42%	0.47%	0.44%	0.37%	0.41%
Gross Profit+	63.63M	79.84M	97.81M	128.55M	143.39M	121.32M	115.53M	177.6M	305.3M	364.17M
Gross Margin %	0.83%	0.62%	0.55%	0.64%	0.69%	0.58%	0.53%	0.56%	0.63%	0.59%
Gross Profit Growth %	0.43%	0.25%	0.23%	0.31%	0.12%	-0.15%	-0.05%	0.54%	0.72%	0.19%
Operating Expenses+	30.93M	53.08M	68.58M	93.19M	127.04M	137.33M	155.32M	212.88M	258.33M	363.58M
OpEx % of Revenue	0.41%	0.41%	0.39%	0.46%	0.62%	0.66%	0.72%	0.67%	0.53%	0.59%
Selling, General & Admin	21.16M	27.83M	31.58M	44.06M	55.84M	64.99M	84.29M	124.04M	161.7M	249.64M
SG&A % of Revenue	0.28%	0.22%	0.18%	0.22%	0.27%	0.31%	0.39%	0.39%	0.33%	0.41%
Research & Development	2.87M	2.91M	9.07M	15.39M	19.81M	16M	11.37M	22.32M	34.29M	44.58M
R&D % of Revenue	0.04%	0.02%	0.05%	0.08%	0.1%	0.08%	0.05%	0.07%	0.07%	0.07%
Other Operating Expenses	41K	-74K	55K	-550K	51.39M	56.35M	59.66M	66.52M	62.35M	69.36M
Operating Income+	32.7M	20.08M	28.33M	35.36M	16.35M	-16.02M	-39.79M	-35.28M	46.97M	584K
Operating Margin %	0.43%	0.16%	0.16%	0.18%	0.08%	-0.08%	-0.18%	-0.11%	0.1%	0%
Operating Income Growth %	0.63%	-0.39%	0.41%	0.25%	-0.54%	-1.98%	-1.48%	0.11%	2.33%	-0.99%
EBITDA+	39.6M	42.42M	56.26M	69.1M	60.96M	28.62M	7.46M	24.37M	106.76M	68.31M
EBITDA Margin %	0.52%	0.33%	0.32%	0.34%	0.3%	0.14%	0.03%	0.08%	0.22%	0.11%
EBITDA Growth %	0.66%	0.07%	0.33%	0.23%	-0.12%	-0.53%	-0.74%	2.27%	3.38%	-0.36%
D&A (Non-Cash Add-back)	6.9M	22.34M	27.93M	33.74M	44.61M	44.64M	47.25M	59.65M	59.79M	67.73M
EBIT	32.7M	33.96M	29.23M	34.81M	16.12M	-16.51M	-44.14M	-34.61M	46.81M	-4.61M
Net Interest Income+	-11.01M	-11.33M	-12.04M	-14.76M	-12.97M	-9.45M	-11.92M	-28.05M	-26.94M	-17.6M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	11.01M	11.33M	12.04M	14.76M	12.97M	9.45M	11.92M	28.05M	26.94M	17.6M
Other Income/Expense	-10.97M	-11.4M	-11.98M	-15.31M	-13.19M	-9.95M	-16.27M	-27.38M	-27.1M	-22.8M
Pretax Income+	21.73M	8.68M	16.35M	20.05M	3.16M	-25.96M	-56.06M	-62.66M	19.87M	-22.21M
Pretax Margin %	0.28%	0.07%	0.09%	0.1%	0.02%	-0.12%	-0.26%	-0.2%	0.04%	-0.04%
Income Tax+	6.36M	4.74M	17.43M	4.56M	-2.94M	-3.41M	-13.46M	-14.77M	1.09M	-3.69M
Effective Tax Rate %	0.71%	0.45%	-0.07%	0.77%	1.93%	0.87%	0.76%	0.76%	0.94%	0.83%
Net Income+	15.38M	3.93M	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M
Net Margin %	0.2%	0.03%	-0.01%	0.08%	0.03%	-0.11%	-0.2%	-0.15%	0.04%	-0.03%
Net Income Growth %	-0.47%	-0.74%	-1.27%	15.4%	-0.61%	-4.7%	-0.89%	-0.12%	1.39%	-1.99%
Net Income (Continuing)	15.38M	3.93M	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.32	0.34	-0.09	1.32	0.50	-1.88	-3.40	-3.05	0.94	-1.04
EPS Growth %	-0.49%	-0.74%	-1.27%	15.16%	-0.62%	-4.76%	-0.81%	0.1%	1.31%	-2.11%
EPS (Basic)	1.34	0.34	-0.09	1.33	0.51	-1.88	-3.40	-3.05	0.95	-1.04
Diluted Shares Outstanding	11.56M	11.57M	11.55M	11.77M	12.04M	11.96M	12.6M	16.26M	18.19M	19.32M
Basic Shares Outstanding	11.37M	11.45M	11.55M	11.68M	11.84M	11.96M	12.6M	16.26M	18M	19.32M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	192.58M	103.01M	131.6M	152.88M	187.69M	170.32M	321.77M	344.26M	519.82M	527.68M
Cash & Short-Term Investments	154.68M	27.36M	31.14M	43.01M	62.33M	7.86M	100.3M	48.23M	221.12M	151.17M
Cash Only	154.68M	27.36M	31.14M	43.01M	62.33M	7.86M	100.3M	48.23M	221.12M	144.86M
Short-Term Investments	0	0	0	0	0	0	0	0	0	6.31M
Accounts Receivable	21.93M	45.9M	58.79M	64.84M	72.13M	95.79M	128.53M	165.44M	162.08M	221.73M
Days Sales Outstanding	104.89	130.24	121.34	117.41	127.46	167.72	217.05	190.86	121.52	131.73
Inventory	13.39M	26.18M	37.73M	40.5M	48.16M	60.8M	81.69M	105.36M	111.2M	136.78M
Days Inventory Outstanding	384.99	195.92	174.24	202.45	278.36	254.63	296.37	277.08	223.6	199.53
Other Current Assets	1.45M	3.56M	2.78M	4.52M	4M	0	3.67M	21.41M	25.42M	18.01M
Total Non-Current Assets+	92.68M	219.86M	280.53M	277.73M	269.09M	290.87M	449.82M	415.83M	384.61M	756.01M
Property, Plant & Equipment	7.13M	11M	20.4M	38.09M	40.55M	41.27M	52.67M	43.25M	44.59M	56.86M
Fixed Asset Turnover	10.70x	11.70x	8.67x	5.29x	5.09x	5.05x	4.10x	7.32x	10.92x	10.80x
Goodwill	1.84M	1.84M	1.84M	3.58M	3.58M	3.58M	27.89M	28.22M	28.22M	59.99M
Intangible Assets	66.4M	175.79M	229.79M	201.6M	180.39M	188.51M	294.12M	251.63M	209.01M	541.83M
Long-Term Investments	-17.32M	5M	800K	5.02M	0	5M	5M	0	6.2M	0
Other Non-Current Assets	17.32M	0	5.04M	1.47M	6.25M	802K	2.21M	11.36M	5.87M	12.22M
Total Assets+	285.26M	322.86M	412.14M	430.6M	456.79M	461.19M	771.6M	760.09M	904.42M	1.28B
Asset Turnover	0.27x	0.40x	0.43x	0.47x	0.45x	0.45x	0.28x	0.42x	0.54x	0.48x
Asset Growth %	0.08%	0.13%	0.28%	0.04%	0.06%	0.01%	0.67%	-0.01%	0.19%	0.42%
Total Current Liabilities+	11.76M	31.95M	39.23M	165.55M	61.68M	78.56M	87.54M	99.44M	145.48M	193.68M
Accounts Payable	2.07M	3.39M	3.63M	8.88M	14.61M	11.26M	22.97M	29.3M	36.68M	45.66M
Days Payables Outstanding	59.41	25.36	16.76	44.41	84.42	47.16	83.32	77.07	73.76	66.6
Short-Term Debt	0	0	3.35M	115.72M	9.94M	13.24M	850K	850K	850K	9.17M
Deferred Revenue (Current)	0	0	1000K	711K	451K	80K	87K	0	0	0
Other Current Liabilities	8.5M	8.15M	29.94M	31.69M	20.33M	33.39M	44.27M	43.71M	65.73M	77.03M
Current Ratio	16.38x	3.22x	3.35x	0.92x	3.04x	2.17x	3.68x	3.46x	3.57x	2.72x
Quick Ratio	15.24x	2.40x	2.39x	0.68x	2.26x	1.39x	2.74x	2.40x	2.81x	2.02x
Cash Conversion Cycle	430.46	300.8	278.81	275.45	321.41	375.19	430.1	390.87	271.36	264.66
Total Non-Current Liabilities+	113.43M	121.27M	198.15M	67.79M	182.32M	186.93M	325.32M	322.11M	301.35M	661.49M
Long-Term Debt	113.43M	120.64M	198.15M	67.3M	175.81M	172.44M	286.52M	285.67M	284.82M	614.92M
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	7.59M	9.49M	0	0	0
Other Non-Current Liabilities	0	625K	0	496K	6.51M	14.48M	38.8M	36.44M	16.53M	46.57M
Total Liabilities	125.18M	153.22M	237.38M	233.34M	244M	265.49M	412.86M	421.55M	446.82M	855.17M
Total Debt+	113.43M	120.64M	201.51M	183.01M	185.75M	185.69M	287.37M	286.52M	285.67M	624.09M
Net Debt	-41.26M	93.28M	170.36M	140.01M	123.42M	177.82M	187.07M	238.29M	64.55M	479.23M
Debt / Equity	0.71x	0.71x	1.15x	0.93x	0.87x	0.95x	0.80x	0.85x	0.62x	1.46x
Debt / EBITDA	2.86x	2.84x	3.58x	2.65x	3.05x	6.49x	38.53x	11.76x	2.68x	9.14x
Net Debt / EBITDA	-1.04x	2.20x	3.03x	2.03x	2.02x	6.21x	25.08x	9.78x	0.60x	7.02x
Interest Coverage	2.97x	1.77x	2.35x	2.40x	1.26x	-1.69x	-3.34x	-1.26x	1.74x	0.03x
Total Equity+	160.08M	169.65M	174.76M	197.26M	212.79M	195.7M	358.74M	338.54M	457.6M	428.53M
Equity Growth %	0.15%	0.06%	0.03%	0.13%	0.08%	-0.08%	0.83%	-0.06%	0.35%	-0.06%
Book Value per Share	13.85	14.66	15.13	16.76	17.67	16.36	28.48	20.82	25.15	22.18
Total Shareholders' Equity	160.08M	169.65M	174.76M	197.26M	212.79M	195.7M	358.74M	338.54M	457.6M	428.53M
Common Stock	1K	1K	1K	1K	1K	1K	1K	1K	2K	2K
Retained Earnings	-4.35M	-2.92M	-4.01M	11.49M	17.58M	-4.97M	-47.77M	-97.29M	-80.13M	-100.28M
Treasury Stock	0	0	-259K	-659K	-723K	-2.25M	-3.13M	-5.09M	-10.08M	-21.04M
Accumulated OCI	-4.45M	-5.39M	-6.59M	-379K	-4.87M	-11.44M	-3.06M	12.17M	8.86M	5.34M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	17.26M	27.47M	39.42M	67.07M	45.63M	15.27M	3.32M	-31.2M	118.96M	64.02M
Operating CF Margin %	0.23%	0.21%	0.22%	0.33%	0.22%	0.07%	0.02%	-0.1%	0.24%	0.1%
Operating CF Growth %	-0.22%	0.59%	0.43%	0.7%	-0.32%	-0.67%	-0.78%	-10.39%	4.81%	-0.46%
Net Income	15.38M	3.93M	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M
Depreciation & Amortization	6.9M	22.34M	27.93M	33.74M	44.61M	44.64M	47.25M	59.65M	59.79M	67.73M
Stock-Based Compensation	3.86M	6.07M	6.09M	6.78M	9.22M	12.94M	10.49M	14.6M	20.65M	29.34M
Deferred Taxes	-1.88M	-8.91M	3.56M	-5.18M	-9.13M	-13.21M	-16.75M	-15.25M	-11.74M	-21.91M
Other Non-Cash Items	6.87M	13.97M	8.57M	10.27M	9.42M	6.07M	5.02M	8.99M	6.62M	18.56M
Working Capital Changes	-13.86M	-9.93M	-5.65M	5.97M	-14.58M	-12.63M	-84K	-51.3M	24.86M	-11.19M
Change in Receivables	-4.63M	-23.96M	-12.89M	-4.74M	-7.29M	-23.66M	-5.55M	-36.91M	3.36M	-21.09M
Change in Inventory	-5.87M	-1.94M	5.36M	-379K	-7.66M	-2.76M	3.22M	-23.63M	-5.84M	-21.29M
Change in Payables	-1.03M	1.08M	3K	3.47M	5.04M	-2.29M	10.17M	5.04M	7.55M	479K
Cash from Investing+	-32.68M	-154.06M	-107.99M	-27.38M	-27.55M	-68.32M	-105.48M	-15.74M	-18.51M	-404.72M
Capital Expenditures	-32.68M	-149.06M	-107.99M	-10.91M	-27.55M	-6.13M	-2.56M	-8.88M	-8.87M	-16.24M
CapEx % of Revenue	0.43%	1.16%	0.61%	0.05%	0.13%	0.03%	0.01%	0.03%	0.02%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-30.5M	-5M	-97.62M	-5.17M	0	-62.19M	-18.43M	-6.83M	-9.64M	12.8M
Cash from Financing+	1.07M	-729K	72.36M	-27.82M	1.25M	-1.44M	194.59M	-5.13M	67.44M	264.94M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-190K	-1.63M	-1.63M	-1.63M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.18M	323K	-2.38M	-24.34M	-118.75M	618K	2.07M	1.46M	-3.5M	-67.69M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-15.42M	-121.59M	-68.57M	56.16M	18.08M	-53.05M	-20.32M	-47.66M	100.45M	47.06M
FCF Margin %	-0.2%	-0.95%	-0.39%	0.28%	0.09%	-0.25%	-0.09%	-0.15%	0.21%	0.08%
FCF Growth %	-0.12%	-6.89%	0.44%	1.82%	-0.68%	-3.93%	0.62%	-1.35%	3.11%	-0.53%
FCF per Share	-1.33	-10.51	-5.94	4.77	1.50	-4.43	-1.61	-2.93	5.52	2.44
FCF Conversion (FCF/Net Income)	1.12x	6.98x	-36.63x	4.33x	7.49x	-0.68x	-0.08x	0.65x	6.33x	-3.46x
Interest Paid	4.15M	4.08M	3.76M	6.29M	6.09M	6.93M	9.71M	21.48M	31.43M	24.38M
Taxes Paid	13.26M	9.54M	17.79M	6.4M	10.03M	4.98M	10.37M	288K	1.23M	19.06M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.25%	2.39%	-0.62%	8.33%	2.97%	-11.04%	-15.37%	-13.74%	4.72%	-4.18%
Return on Invested Capital (ROIC)	24.49%	7.89%	6.99%	7.77%	3.64%	-3.38%	-6.49%	-4.71%	6.41%	0.06%
Gross Margin	83.37%	62.07%	55.31%	63.77%	69.42%	58.19%	53.45%	56.13%	62.71%	59.27%
Net Margin	20.14%	3.06%	-0.61%	7.69%	2.95%	-10.82%	-19.71%	-15.14%	3.86%	-3.01%
Debt / Equity	0.71x	0.71x	1.15x	0.93x	0.87x	0.95x	0.80x	0.85x	0.62x	1.46x
Interest Coverage	2.97x	1.77x	2.35x	2.40x	1.26x	-1.69x	-3.34x	-1.26x	1.74x	0.03x
FCF Conversion	1.12x	6.98x	-36.63x	4.33x	7.49x	-0.68x	-0.08x	0.65x	6.33x	-3.46x
Revenue Growth	36.36%	68.53%	37.49%	13.99%	2.47%	0.93%	3.67%	46.38%	53.87%	26.2%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Sales of Generics and Other	-	-	-	-	-	-	-	-	-	320.03M
Total Sales of Generics and Other Growth	-	-	-	-	-	-	-	-	-	-
Sales of rare disease pharmaceutical products	-	-	-	-	-	-	-	-	112.12M	229.6M
Sales of rare disease pharmaceutical products Growth	-	-	-	-	-	-	-	-	-	104.79%
Sales of Established Brands	-	-	-	-	-	-	-	-	-	64.74M
Sales of Established Brands Growth	-	-	-	-	-	-	-	-	-	-
Rare Disease	-	-	-	-	-	-	-	41.69M	269.45M	-
Rare Disease Growth	-	-	-	-	-	-	-	-	546.36%	-
Generics, Established Brands, and Other	-	-	-	-	-	-	-	274.7M	105.25M	-
Generics, Established Brands, and Other Growth	-	-	-	-	-	-	-	-	-61.69%	-
Sales of generic pharmaceutical products	-	-	-	-	-	-	143.57M	-	-	-
Sales of generic pharmaceutical products Growth	-	-	-	-	-	-	-	-	-	-
Sales of branded pharmaceutical products	-	-	-	-	-	-	47.56M	-	-	-
Sales of branded pharmaceutical products Growth	-	-	-	-	-	-	-	-	-	-
Royalties from licensing agreements	-	-	-	-	-	-	11.79M	-	-	-
Royalties from licensing agreements Growth	-	-	-	-	-	-	-	-	-	-
Sales of contract manufactured products	-	-	-	-	-	-	3.8M	-	-	-
Sales of contract manufactured products Growth	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	1.86M	-	-	-
Other Growth	-	-	-	-	-	-	-	-	-	-
Product development services	-	-	-	-	-	-	1.31M	-	-	-
Product development services Growth	-	-	-	-	-	-	-	-	-	-
Sales Of Generic Pharmaceutical Products	-	-	-	117.45M	-	147.26M	-	-	-	-
Sales Of Generic Pharmaceutical Products Growth	-	-	-	-	-	-	-	-	-	-
Sales Of Branded Pharmaceutical Products	-	-	-	60.55M	-	47.96M	-	-	-	-
Sales Of Branded Pharmaceutical Products Growth	-	-	-	-	-	-	-	-	-	-
Sales Of Contract Manufactured Products	-	-	-	6.3M	8.1M	6.8M	-	-	-	-
Sales Of Contract Manufactured Products Growth	-	-	-	-	28.57%	-16.05%	-	-	-	-
Product Development Services	-	-	-	1.02M	-	1.86M	-	-	-	-
Product Development Services Growth	-	-	-	-	-	-	-	-	-	-
Royalties From Licensing Agreements	-	-	-	12.5M	-	1.4M	-	-	-	-
Royalties From Licensing Agreements Growth	-	-	-	-	-	-	-	-	-	-
Other Revenues	-	-	-	929K	-	783K	-	-	-	-
Other Revenues Growth	-	-	-	-	-	-	-	-	-	-
Performance Obligation From Prior Period	-	-	-	-	10.2M	-	-	-	-	-
Performance Obligation From Prior Period Growth	-	-	-	-	-	-	-	-	-	-
Products Development Services	-	-	-	-	1.3M	-	-	-	-	-
Products Development Services Growth	-	-	-	-	-	-	-	-	-	-
Unapproved Products	300K	34.3M	27.6M	-	-	-	-	-	-	-
Unapproved Products Growth	-	11333.33%	-19.53%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	604.99M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
Non-US	-	-	-	-	-	-	-	-	-	9.39M
Non-US Growth	-	-	-	-	-	-	-	-	-	-
United States	-	-	-	196.89M	199.66M	-	211.89M	312.43M	486.25M	-
United States Growth	-	-	-	-	1.41%	-	-	47.45%	55.64%	-
Canada	-	-	-	4.69M	6.88M	-	4.24M	3.96M	565K	-
Canada Growth	-	-	-	-	46.78%	-	-	-6.72%	-85.73%	-
U	-	-	-	-	-	202.88M	-	-	-	-
U Growth	-	-	-	-	-	-	-	-	-	-
C	-	-	-	-	-	5.59M	-	-	-	-
C Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ANI Pharmaceuticals, Inc. (ANIP) reported $826.9M in revenue for fiscal year 2024. This represents a 189917% increase from $0.4M in 2011.

ANI Pharmaceuticals, Inc. (ANIP) grew revenue by 26.2% over the past year. This is strong growth.

Yes, ANI Pharmaceuticals, Inc. (ANIP) is profitable, generating $38.1M in net income for fiscal year 2024 (-3.0% net margin).

Dividend & Returns

ANI Pharmaceuticals, Inc. (ANIP) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.

ANI Pharmaceuticals, Inc. (ANIP) has a return on equity (ROE) of -4.2%. Negative ROE indicates the company is unprofitable.

ANI Pharmaceuticals, Inc. (ANIP) generated $135.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.